Phathom Pharmaceuticals (PHAT) Cash from Financing Activities (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Cash from Financing Activities data on file, last reported at $66.6 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities changed N/A year-over-year to $66.6 million in Q1 2026; TTM through Mar 2026 was $66.4 million, a 61.62% decrease from a year earlier, with the FY2025 full-year figure at -$288000.0, down 100.16% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $66.6 million, up from -$97000.0 in the prior quarter.
• Over the last five years, Cash from Financing Activities for PHAT reached as high as $212.0 million in Q4 2023 and fell as low as -$271000.0 in Q3 2025.
• Historically, Cash from Financing Activities has averaged $49.3 million across 5 years, with a median of $24.6 million in 2022.
• Across the five-year window, Cash from Financing Activities soared 938800.0% in 2024 and plunged 100.37% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $24.6 million in 2022, then jumped by 761.9% to $212.0 million in 2023, then slumped by 87.71% to $26.0 million in 2024, then plunged by 100.37% to -$97000.0 in 2025, then surged by 68801.03% to $66.6 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $66.6 million in Q1 2026, -$97000.0 in Q4 2025, and -$271000.0 in Q3 2025.